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Objective: The aim of this work was to determine the prevalence and progression of epilepsy in adult patients with
mitochondrial disease.
Methods: We prospectively recruited a cohort of 182 consecutive adult patients attending a specialized mitochon-
drial disease clinic in Newcastle upon Tyne between January 1, 2005 and January 1, 2008. We then followed this
cohort over a 7-year period, recording primary outcome measures of occurrence of first seizure, status epilepticus,
stroke-like episode, and death.
Results: Overall prevalence of epilepsy in the cohort was 23.1%. Mean age of epilepsy onset was 29.4 years. Preva-
lence varied widely between genotypes, with several genotypes having no cases of epilepsy, a prevalence of 34.9%
in the most common genotype (m.3243A>G mutation), and 92.3% in the m.8344A>G mutation. Among the cohort
as a whole, focal seizures, with or without progression to bilateral convulsive seizures, was the most common seizure
type. Conversely, all of the patients with the m.8344A>G mutation and epilepsy experienced myoclonic seizures.
Patients with the m.3243A>G mutation remain at high risk of developing stroke-like episodes (1.16% per year). How-
ever, although the standardized mortality ratio for the entire cohort was high (2.86), this ratio did not differ signifi-
cantly between patients with epilepsy (2.96) and those without (2.83).
Interpretation: Epilepsy is a common manifestation of mitochondrial disease. It develops early in the disease and, in
the case of the m.3243A>G mutation, often presents in the context of a stroke-like episode or status epilepticus.
However, epilepsy does not itself appear to contribute to the increased mortality in mitochondrial disease.
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Mitochondrial diseases are a diverse group of multi-system disorders caused by mutations of mitochon-
drial DNA (mtDNA).1,2 Mitochondria are the main
source of cellular adenosine triphosphate through the
process of oxidative phosphorylation, and common to all
mitochondrial disease is the vulnerability of highly
energy-dependent tissues such as skeletal muscle and
brain.3 There are many different genetic defects of
mtDNA, including both point mutations and large-scale
rearrangements and deletions. In general, a given genetic
defect may cause a specific clinical syndrome, but the
relationship between genotype and phenotype is not
absolute and there is considerable overlap between syn-
dromes.4 Nevertheless, some clinical features are more
common in certain genotypes. Thus, for example, central
nervous system (CNS) involvement is common in the
m.3243A>G and m.8344A>G point mutations,5 but
relatively rare in patients with single mtDNA deletions.6
In adults with mitochondrial disease, CNS involve-
ment includes progressive cognitive decline,7 migraine,8
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and epilepsy. Some genotypes produce relatively specific
CNS syndromes. For example, in the syndrome of Mito-
chondrial Encephalomyopathy, Lactic Acidosis and
Stroke-Like Episodes, most commonly resulting from the
m.3243A>G point mutation,9,10 patients suffer repeated
episodes of encephalopathy and stroke-like episodes, usu-
ally accompanied by focal seizures in the parietal and
occipital lobes. Focal and generalized status epilepticus
can occur in association with these stroke-like episodes.
In other syndromes, for example, Myoclonic Epilepsy
with Ragged Red Fibers, usually as a result of the
m.8344A>G point mutation, epilepsy is one of the
defining clinical features and typically manifests as gener-
alized myoclonus with photosensitivity.11–14 As with
other clinical features, the type of epilepsy found only
partially reflects the underlying genotype, with a large
degree of overlap found between syndromes.15,16
Although there have been many reports of epilepsy
in mitochondrial disease, these have tended to be in
either pediatric series and/or of small numbers of adult
patients with sometimes poorly defined molecular
defects.17–19 Furthermore, the prevalence rates for epi-
lepsy vary widely between reports.20,21 In this article, we
present the first large-scale cross-sectional cohort study of
the prevalence and classification of epilepsy in genetically
defined adult patients with mitochondrial disease and
define, for the first time, the epilepsy-related morbidity
and mortality in these patients.
Subjects/Materials and Methods
All consecutive adult patients (defined as age 16 years or
over) attending a specialist mitochondrial clinic between
May 1, 2005 and May 1, 2008 were included in the
study. Our center in Newcastle upon Tyne provides one of
three nationally commissioned specialist mitochondrial dis-
ease clinics and receives referrals from throughout the UK
and Ireland. One hundred eighty-two different patients
(98 females, 84 males) were observed during this period.
Mean age at recruitment to the cohort was 37.8 years
(range, 16–58). All patients had proven mitochondrial dis-
ease on the basis of molecular genetic, biochemical, and
histochemical analysis and were classified on the basis of
their genetic diagnosis. Patients were screened by a consul-
tant neurologist using the Newcastle Mitochondrial Dis-
ease Adult Scale, a validated rating scale that includes a
question on current or past history of epileptic seizures.22
Patients with a history of epilepsy were then further inter-
viewed either in clinic or over the telephone to determine
seizure frequency and type according to the 1989 Interna-
tional League Against Epilepsy (ILAE) classification.23
These were subsequently reclassified according to the 2010
revised ILAE guidelines.24 Epilepsy was defined as any his-
tory of more than one unprovoked seizure or a period of
status epilepticus. Active epilepsy was defined either as one
or more seizures within the previous 12 months and a his-
tory of previous seizures, two or more seizures in the pre-
ceding 12-month period with no history of previous
seizures, or a period of status epilepticus with or without a
previous history of epilepsy. Where patients had more
than one seizure type, these were classified as primary, sec-
ondary, or tertiary based on seizure frequency rather than
order of presentation. The hospital notes of all patients
were also reviewed in case any patient was not aware of
having had previous seizures, and to identify causes of epi-
lepsy other than mitochondrial disease.
The electroencephalograms (EEGs) of all patients
were reviewed by a consultant clinical neurophysiologist
(R.G.W.), and in patients who had a previous EEG this
was not repeated unless clinically indicated. Where
patients had undergone several EEGs, the most recent
was reviewed. Abnormalities were scored according to the
criteria used in the SANAD study.25
Having defined our initial cohort, we then followed
up these patients through their routine clinic appoint-
ments. These typically occurred at intervals of 6 or 12
months. Patients were asked at each visit about the
occurrence of seizures or stroke-like episodes. A further
review of the hospital notes was performed in 2015 to
ensure that no history of epilepsy had been missed. Out-
come measures were the development of epilepsy in those
initially seizure free, the occurrence of significant seizure-
related morbidities (ie, stroke-like episodes or status epi-
lepticus), and death. For all outcome measures, person
time at risk was calculated for each individual patient
from the year of recruitment to the study. Standardized
mortality ratios were calculated using data from the UK
Office for National Statistics mortality data, 2010. These
data are subdivided into <15, 15 to 34, 35 to 59, 60 to
79, and >80 years age ranges, and the age range within
which the mean age of each subgroup fell was used as
the denominator in calculations of standardized mortality
ratios. The study was approved by Newcastle and North
Tyneside Local Research Ethics Committee.
Results
Point Prevalence and Phenotype of Epilepsy
One hundred eighty-two different patients were seen
between May 1, 2005 and May 1, 2008. Forty-two of these
had a history of epilepsy, giving a combined prevalence of
epilepsy for all genotypes of 23.1% on May 1, 2008
(Figure 1, Table 1). Thirty-five patients (19.2%) had active
epilepsy, whereas the remaining 7 (3.8%) had a previous
history of epilepsy but with no seizures in the 12-month
period preceding inclusion. Mean age of onset was 29.4
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years (range, 2–58). Epilepsy was a feature of the eight dif-
ferent genotypes of mitochondrial disease listed below.
M.3243A>G MUTATION. Sixty-three patients with the
m.3243A>G point mutation were included. This group
included asymptomatic carriers, patients with isolated
diabetes and deafness, and patients with MELAS syn-
drome. Twenty-two of the patients with the
m.3243A>G point mutation (34.9%) had epilepsy.
These patients represented 12.1% of the entire cohort.
Mean age of epilepsy onset was 32.6 years (range, 9–56).
Five of the 22 patients with a history of epilepsy
(22.7%) were seizure free at the time of assessment. In
the patients with epilepsy, the most common seizure phe-
notype was focal motor seizures (12 of 225 54.5%). Ten
patients (45.5%) had focal seizures evolving to bilateral
convulsive seizures. Focal sensory seizures were noted in
5 (22.7%) and focal dyscognitive, or myoclonic, seizures
were each noted in 4 (18.2%) of the patients. Three
patients (13.6%) had tonic-clonic seizures.
Eighteen patients had had an EEG; in 4 patients, this
was normal, and 14 showed a slowing in background brain
activity. Focal, multifocal, and generalized epileptiform
abnormalities were noted in 4, 4, and 3 patients, respectively.
M.8344A>G MUTATION. Thirteen patients with the
m.8344A>G point mutation were included. Twelve of
these 13 (92.3%) patients had epilepsy, and all of these
had myoclonic seizures. These patients represented 6.6%
of the entire cohort. The mean age of epilepsy onset was
23.8 years (range, 18–58). In many patients, the myo-
clonic jerks were subtle and were only revealed on direct
questioning. Two patients (16.7%) also had infrequent
(<1/month) tonic-clonic seizures in response to photic
stimulation, for example, strobe lighting in nightclubs, or
when a passenger in a car. Because these patients had
learned to avoid these precipitants, their tonic-clonic seiz-
ures occurred less than once a month. Despite experienc-
ing daily myoclonic jerks, 3 of these patients were not
taking antiepileptic medication.
Ten patients had EEGs performed; in 8 of these,
the background was slow, and generalized epileptiform
abnormalities were noted in 6 patients. Despite the
FIGURE 1: (A) Prevalence of epilepsy among a cohort of 182 adult patients with mitochondrial disease. Overall prevalence of
epilepsy was 23.1%. The genotypes most commonly associated with epilepsy were m.3243A>G, m.8344A>G, and recessive
POLG mutations and represented 11.8%, 6.4%, and 1.6% of the total cohort, respectively. One patient each with the
m.12147A>G mutation, m.8993T>G mutation, single large-scale deletion, multiple mtDNA deletions, and recessive TRIT1 muta-
tions had epilepsy; together, this group represented 2.7% of the total cohort. (B) Seizure phenotypes for the eight genotypes
in which epilepsy occurred. The total number of seizure types is greater than the number of patients with epilepsy because
several patients had more than one seizure type. mtDNA5mitochondrial DNA.
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clinical history of photosensitivity in 4 patients, only 1
showed a photoparoxysmal response on their EEG.
RECESSIVE POLG MUTATIONS. Thirteen patients
were included, of whom 3 (23.1%) had epilepsy. These
patients represented 1.6% of the entire cohort. Mean age
of epilepsy onset was 27.5 years (range, 26–33). One
patient (biallelic p.(Trp748Ser) and p.(Arg1096Cys) var-
iants) had both myoclonic and tonic-clonic seizures on a
daily basis. An EEG at age 55 showed a slow background
with multifocal epileptiform abnormalities. The second
patient (recessive p.(Ala467Thr) and p.(X1240Q) had
infrequent (<1/month) focal dyscognitive seizures. An
EEG at age 42 showed a slow background with no epi-
leptiform abnormalities. The third patient
(p.(Ala467Thr) and p.(Arg1096Cys) variants) had previ-
ously had myoclonic seizures, but was currently seizure
free and on no medication. An EEG at age 45 showed a
slow background with no epileptiform abnormalities.
SINGLE DELETION. Thirty-three patients with a single,
large-scale mtDNA deletion were included. Only 1 of
these patients had epilepsy (3.0%) with focal dyscognitive
seizures occasionally evolving to bilateral convulsive seiz-
ures occurring less than once a month. The patient had
presented at the age of 5 years with seizures, for which
no cause was detected. It was more than 20 years later
that the patient presented with ptosis and a diagnosis of
mitochondrial disease was made. No EEGs were available
from his original presentation with epilepsy and this was
not repeated.
MULTIPLE MTDNA DELETIONS. Fourteen patients
with multiple mtDNA deletions for which no nuclear gene
defect of mtDNA maintenance could be determined were
included. One of these 14 patients (7.1%) had epilepsy.
This patient presented at the age of 2 years with a mixture
of focal motor and bilateral convulsive seizures. She had
remained seizure free on two antiepileptic drugs until the
age of 59, when she represented with a further flurry of
focal motor seizures. She had a normal EEG age 59.
M.12147G>A MUTATION. Only 1 patient with this
rare mtDNA genotype was included. This patient pre-
sented at age 17 with a devastating MELAS-like phenotype
with encephalopathy, stroke-like episode, and focal status
epilepticus affecting the right temporal lobe. The degree of
edema after the stroke-like episode was so great that a tem-
poral lobectomy was performed in order to reduce intracra-
nial pressure. At the time of assessment at age 26, the
patient was seizure free on carbamazepine. An EEG per-
formed at the age of 23 showed a slow background with
focal epileptiform abnormalities over the temporal region.
TABLE 1. Prevalence and Seizure Phenotypes in Patients With Mitochondrial Disease and Epilepsy
Genotype Prevalence of
Epilepsy
Age at First
Seizure (mean,
range)
1  2  3  SLE SE
Overall 42/182 (23.1%) 29.4 (2–58)
m.3243A>G 22/63 (34.9%) 32.6 (9–56) FM (54.5%) BC (45.5%) FS
(22.7%)
17.5% 7.9%
m.8344A>G 12/13 (92.3%) 23.8 (18-58) M (100%) TC (16.7%) 0% 0%
POLG1 3/13 (23.1%) 27.5 (26–33) M (66.7%) TC (33.3%) FDS
(33.3%)
0% 0%
Single mtDNA
deletion
1/33 (3%) 5 (n/a) FDS (100%) BC (100%) 0% 0%
Multiple mtDNA
deletions
1/14 (7.1%) 2 (n/a) FM (100%) BC (100%) 0% 0%
m.12147A>G 1/1 (100%) 17 (n/a) FM (100%) BC (100%) 100% 100%
m.8993T>G 1/1 (100%) 19 (n/a) M (100%) TC (100%) 0% 0%
p.(Arg323Gln)
TRIT1
1/1 (100%) 10 (n/a) M (100%) TC (100%) 0% 0%
Estimates of prevalence are taken at the time of cohort closure on May 1, 2008. 1 5most common seizure type; 2 5 second
most common seizure type; 3 5 third most common seizure type.
M5myoclonic; FM5 focal motor; FS5 focal sensory; FDS5 focal dyscognitive; TC5 tonic-clonic; BC5 focal seizures evolving
to bilateral convulsive seizure; SLE5 stroke-like episode; SE5 status epilepticus; n/a5 not applicable.
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M.8993T>G MUTATION. One patient with the
m.8993T>G point mutation was included, commonly
associated with NARP (neuropathy, ataxia, retinitis pig-
mentosa) syndrome. This patient presented at age 19
with both myoclonic and tonic-clonic seizures at a fre-
quency of greater than once a month. An EEG per-
formed at age 38 showed a slow background with
generalized epileptiform abnormalities.
RECESSIVE TRIT1 MUTATION. One patient homozy-
gous for a TRIT1 missense mutation was included. This
patient developed seizures at age 10 years. He suffered
infrequent (<1/month) myoclonic absence and bilateral
convulsive seizures. An EEG performed at the age of 23
showed a normal background with focal epileptiform
abnormalities over both temporal lobes.
Other genotypes in the cohort in which no epilepsy
was found were: PEO1 (n5 13), OPA1 (n5 7),
m.14709T>C (n5 5), RRM2B (n5 4), m.12258A>G
(n5 2), succinate dehydrogenase deficiency (n5 2), SPG7
(n5 2), m.4298G>A, m.7587T>C, m.7989T>C,
m.618T>G, m.12283G>A, m.1624C>T, TYMP, and
YARS2 (all n5 1).
Follow-up
Patients were followed up between their time of inclusion
to the cohort (May 1, 2005 to May 1, 2008) and Janu-
ary 1, 2015 through their routine clinic appointments.
Total length of follow-up was 1,245 person-years (mean,
6.85; range, 1–10); 944 person-years for patients without
epilepsy and 301 person-years for those with epilepsy.
Patients are referred from throughout the UK and Ire-
land, and 13 cases declined further follow-up in Newcas-
tle because of the large distance involved (2 cases moved
abroad). Three further cases were lost to follow-up for
unknown reasons, and 20 cases died. Nevertheless, our
total of 1,245 years of follow-up represents 87.7% of the
1,419 maximum possible years of follow-up had all sur-
viving patients remained in the cohort until 2015.
Risk of Developing Epilepsy
At the time of cohort closure (May 1, 2008), 140 of the
182 patients did not have a history of epilepsy. Three of
these patients subsequently developed epilepsy during the
period of follow-up. All carried the m.3243A>G muta-
tion. The mean age at which these individuals had their
first seizure was 25 years (range, 20–27), and in each
case this was in the context of a stroke-like episode.
These three events arose from a total of 258 years of
follow-up free from epilepsy among the m.3243A>G
group, giving an approximate risk of developing epilepsy
of 1.2% per year for patients carrying the m.3243A>G
mutation. Because no patient carrying another genetic
mutation developed epilepsy during the period of follow-
up, it is not possible to calculate the risk of developing
epilepsy in these genotypes.
Risk of Stroke-Like Episodes
Eleven of 63 patients (17.5%) with the m.3243A>G
mutation had a previous history of stroke-like episodes at
the time of cohort closure. In 3 of these patients, seizures
occurred exclusively in association with the stroke-like epi-
sodes, these patients remaining seizure free at other times.
A further 4 patients (6.3%) with the m.3243A>G muta-
tion had a first episode of stroke-like episode during the
follow-up period. This included the 3 patients who devel-
oped epilepsy during the follow-up period. In all cases,
the stroke-like episodes were associated with focal seizure
activity, which was treated aggressively with maximal antie-
pileptic medication and intravenous rehydration. These
events arose from a total of 344 years of follow-up free
from stroke-like episode, equating to an approximate risk
of developing a first stroke-like episode of 1.16% per year
in patients carrying the m.3243A>G mutation.
The patient with the m.12147A>G mutation had
initially presented with a stroke-like episode as described
above. He suffered no further events during the follow-
up period. No stroke-like episodes occurred in any of the
other genotypes included in the study.
Risk of Status Epilepticus
Status epilepticus occurred in 5 of the patients with
m.3243A>G mutation (7.9%). In all cases, this was in
the setting of a stroke-like episode, and in all cases this
had occurred before cohort closure in 2008. The patient
with m.12147G>A had presented with status epilepticus
at age 17 years, but was seizure free at the time of cohort
closure. No episodes of status epilepticus were observed
in any of the other genotypes included in the study, and
no further episodes of status epilepticus occurred during
the follow-up period; consequently, it was not possible to
calculate an incidence rate.
Risk of Death
Twenty of the patients with mitochondrial disease died
during the period of follow-up, giving an overall case
fatality rate of 1.61% for all patients with mitochondrial
disease. This comprised 5 of the 42 patients with epi-
lepsy and 15 of the 140 patients without epilepsy.
In the 5 patients with epilepsy who died, 2 patients
died of respiratory failure, 1 from cardiac failure, 1 from
drowning not associate with an epileptic seizure, and in 1
case the cause of death was unknown. In none of these 5
cases was the cause of death thought to be related to an
epileptic seizure or to sudden unexplained death in epilepsy.
This approximates to a case fatality rate in patients with
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mitochondrial disease and epilepsy of 1.66%. The mean
age of patients with epilepsy was 40.2 years, giving a stand-
ardized mortality ratio of 2.96 (95% confidence interval
[CI]: 0.96–6.74) compared to the UK control population.
In the 15 patients without epilepsy who died, the
commonest cause was pneumonia (n5 3), followed by
cardiac failure (n5 2), lung cancer (n5 2), intracerebral
hemorrhage (n5 1), and complications of abdominal sur-
gery (n5 1). One patient died of drowning, but there was
no suggestion that this had occurred as a result of an epi-
leptic seizure. In 5 patients, the cause of death was
unclear. The approximate case fatality rate in patients with
mitochondria disease but without epilepsy was 1.60%.
Mean age of patients without epilepsy was 50.7 years, giv-
ing a standardized mortality ratio of 2.83 (95% CI: 1.59–
4.63) compared to the UK control population.
Discussion
We present the first large-scale cohort study of epilepsy
in adult patients with genetically defined mitochondrial
disease. We find an overall prevalence of epilepsy of
23.1% in this cohort. The Newcastle mitochondrial serv-
ice is one of only three highly specialized referral centers
for the whole of the UK and has been reviewing and
investigating patients with suspected mitochondrial dis-
ease for over two decades. Furthermore, our diagnostic
laboratory carries out all genetic testing for mitochondrial
disease in the region, and strenuous efforts are made to
follow up both affected individuals and their families.
We further attempted to obtain a true prevalence figure
by following up nonattenders at clinic with telephone
interviews. For these reasons, it is unlikely that there are
many adult patients with mitochondrial disease who were
not included in the cohort. Nevertheless, we cannot rule
out bias because of patients with mitochondrial disease
being missed from our study population.
We limited our study population to adult patients
because despite being a national referral center, we felt
that we would not achieve sufficient numbers of pediatric
patients to reach meaningful population-based conclu-
sions. Some pediatric patients with mitochondrial disease
present with a severe epilepsy syndrome and often do
not survive into adulthood. This survival bias undoubt-
edly alters the prevalence in adult patients, and, conse-
quently, our reported incidence and prevalence rates
specifically relate to patients presenting in adulthood.
Strenuous efforts are made to keep in touch with
patients who have been observed within our service, but
inevitably patients who are sometimes traveling hundreds
of miles to attend outpatient appointments decline fur-
ther follow-up. We achieved a follow-up rate of 87.7%
of the maximum possible number of patient years of
follow-up, but accept that our follow-up data are incom-
plete. However, we feel that given our close relationship
with these patients and their families and our recognition
as a national center for the care of these diseases, it is
unlikely that a substantial proportion of those lost to
follow-up will have suffered significant epilepsy-related
morbidity or mortality without our knowledge.
Our cohort included a wide range of genetic
defects, as well as a wide range of severity from severely
affected individuals to oligosymptomatic relatives
detected through family screening. Although we find an
overall prevalence of epilepsy of 23.1% for the cohort as
a whole, there are clear differences between genotypes. In
many genotypes, such as m.14709T>C, OPA1, and
PEO1, no patients with epilepsy were found. Prevalence
in the commonest genotype (m.3243A>G) was 34.9%,
and almost all (92.3%) of the patients with the
m.8344A>G point mutation had seizures. Epilepsy was
also noted in patients with the m.12147G>A,
m.8993T>G, and recessive TRIT1 mutations. However,
only single patients with this genotype were included,
and, consequently, there were no other patients carrying
the same genotype who did not have epilepsy. The true
prevalence in these genotypes therefore cannot be deter-
mined, although the implication is that this may be very
high. One patient each with single large-scale deletion
and multiple mtDNA deletions of unknown nuclear gene
had epilepsy. However, in both cases, the epilepsy had
presented at a very young age, many years before the
diagnosis of mitochondrial disease was made, and it
seems likely that these are secondary to causes other than
mitochondrial disease.
Why these differences in epilepsy risk between
genotypes should exist is largely unknown. Imaging stud-
ies have shown that genotypes with a high prevalence of
epilepsy, such as m.3243A>G and m.8344A>G, tend to
show more changes in the cerebral cortex than genotypes
with a low prevalence of epilepsy, such as large-scale sin-
gle deletion.26 However, why these mutations are prefer-
entially expressed within the brain is largely unexplained.
Within the cortex, cortical interneurons seem particularly
vulnerable to mitochondrial dysfunction,27 but, again,
why these cells are more affected in one genotype versus
another remains largely unknown.
A wide range of seizure phenotypes were observed,
and, unsurprisingly, individual patients could have several
distinct seizure types. Whereas all of the patients with
the m.8344A>G and epilepsy exhibited myoclonic jerks,
for every other genotype the commonest seizure manifes-
tation was with focal seizures. The m.8344A>G muta-
tion shows a largely homogeneous distribution within the
body,28 including in neuronal tissues, and it may be for
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this reason that the commonest seizure type is general-
ized. In contrast, the m.3243A>G mutation shows large
differences in mutation load between and within tis-
sues,29 with a particularly high mutation load in cerebral
vascular smooth muscle cells.30 Energy failure is one
plausible mechanism whereby neuronal dysfunction
develops in mitochondrial disease,31 and it may be that
localized perfusion deficits predispose to focal seizures.
The extreme expression of this potential perfusion/activ-
ity mismatch is the stroke-like episode.32,33 In keeping
with other accounts, we find that all of these events are
associated with focal seizure activity. In all of the cases,
the focal seizure activity was aggressively treated with
maximal antiepileptic medication therapy and intrave-
nous rehydration. Although we cannot be certain that
this influenced outcome, our practice in these cases is to
treat the seizure activity with high doses of intravenous
phenytoin or levetiracetam while avoiding agents such as
sodium valproate in patients with POLG mutations,
because this agent may compromise mitochondrial func-
tion.34 Only 3 patients with other genotypes were taking
sodium valproate during the period of follow-up. In 1
patient with the m.3243A>G mutation, it was effective
in suppressing myoclonic jerks. However, in 1 patient
with the m.8344A>G mutation, it proved ineffective in
controlling myoclonic jerks and was substituted for lamo-
trigine; and in 1 patient with the m.8993T>G mutation,
it proved similarly ineffective. None of these patients suf-
fered any side effects attributable to the medication, sug-
gesting that it is a safe drug to use in patients who do
not harbor POLG mutations. However, it does not
appear to be particularly effective, and given the recent
evidence of the efficacy of levetiracetam in the treatment
of myoclonus in patients with mitochondrial disease,35
we would regard sodium valproate as, at best, a second-
line treatment.
As well as differences in epilepsy prevalence and sei-
zure manifestations, we find significant differences in the
risks of epilepsy-related morbidity. Almost half of the
patients with the m.3243A>G mutation had a previous
history of stroke-like episode, and there was a high risk
(1.16% per year) of developing stroke-like episodes in
the remainder. Interestingly, we found no stroke-like
events in the patients with the POLG mutation. This is
in contrast to the high rates reported in other
cohorts.36,37 We have previously published on this group,
the majority of whom presented with a sensory neuron-
opathy rather than with CNS disease.38 However, 3 fur-
ther patients with the POLG mutation presented after
2008 and were consequently not included. All of these
patients had seizures and stroke-like episodes, suggesting
that the true prevalence of stroke-like episodes in this
genotype may be higher than our cohort suggests.
Although this is the largest cohort study of patients
with mitochondrial disease published so far, the number
of deaths, particularly in the epilepsy group, was small.
Consequently, the confidence intervals on the standar-
dized mortality ratio values are broad. Nevertheless, the
case fatality rates and standardized mortality rates in our
cohort are similar to those published in patients with
other forms of epilepsy.39,40 Interestingly, the standar-
dized mortality rate in our cohort was similar between
patients with and without epilepsy. This and the observa-
tion that none of the deaths were attributed to epilepsy
further suggests that those deaths that did occur were as
a result of complications (primarily cardiorespiratory)
secondary to mitochondrial disease per se rather than any
additional mortality secondary to the presence of
seizures.
Our study reports the first prospective study of the
prevalence of epilepsy in a large cohort of adult patients
with mitochondrial disease. We find a high prevalence of
epilepsy in the cohort as a whole, but with striking dif-
ferences in the prevalence between genotypes. The epi-
lepsy presents at a young age and patients, particularly
those carrying the m.3243A>G mutation, remain at
high risk of status epilepticus and stroke-like episodes.
This information will be of use in offering prognostic
advice to adult patients diagnosed with mitochondrial
disease and is a first step in developing more rational
treatment strategies for those patients in whom epilepsy
develops.
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